Esteatosis hepática: trabajo monográfico

• Autores: Carolina Rodellar Pico, Lorena Saba Huerva, Raquel Mauri Mur, Nerea Gracia Viñuales, María Cesarea Escartín Lanuza, María Luz Pallardo Fernández Molina
• Localización: Revista Sanitaria de Investigación, ISSN-e 2660-7085, Vol. 5, Nº. 12, 2024
• Idioma: español
• Enlaces
  • Texto completo
• Resumen
  • español

    La esteatosis hepática, también conocida como hígado graso, es una patología caracterizada por la acumulación excesiva de lípidos en los hepatocitos. Es un problema creciente en salud pública, especialmente en relación con el aumento de enfermedades metabólicas como la obesidad y la diabetes tipo 2. Existen dos tipos principales: la esteatosis hepática no alcohólica (EHNA) y la alcohólica. La EHNA, de mayor prevalencia, se asocia con el síndrome metabólico y puede evolucionar hacia enfermedades más graves como fibrosis, cirrosis y carcinoma hepatocelular. Este trabajo revisa la etiología, fisiopatología, diagnóstico, manejo y tratamiento de la enfermedad, subrayando la importancia de los cambios en el estilo de vida como pilar en su manejo.

  • English

    Hepatic steatosis, also known as fatty liver, is a pathology characterized by the excessive accumulation of lipids in hepatocytes. It is a growing public health problem, especially in relation to the increase in metabolic diseases such as obesity and type 2 diabetes. There are two main types: non-alcoholic fatty liver disease (NASH) and alcoholic fatty liver disease. NASH, which is more prevalent, is associated with metabolic syndrome and can progress to more serious diseases such as fibrosis, cirrhosis and hepatocellular carcinoma. This work reviews the etiology, pathophysiology, diagnosis, management and treatment of the disease, highlighting the importance of changes in lifestyle as a pillar in its management.

• Referencias bibliográficas
  • Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
  • Younossi ZM, et al. Global epidemiology of NAFLD. Hepatology. 2016;64(1):73-84.
  • Chalasani N, et al. The diagnosis and management of NAFLD. Hepatology. 2012;55(6):2005-23.
  • Marchesini G, et al. Nonalcoholic fatty liver disease and metabolic syndrome. Curr Opin Lipidol. 2001;12(3):239-45.
  • Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to NAFLD. Nat Genet. 2008;40(12):1461-65.
  • Musso G, et al. Dietary habits and NAFLD. Gastroenterology. 2011;140(3):1012-28.
  • Stickel F, et al. Alcoholic liver disease. Lancet. 2017;389(10085):101-12.
  • Seitz HK, et al. Alcohol and cancer. Alcohol Alcohol. 2012;47(3):219-27.
  • Sanyal AJ. Mechanisms of disease: NAFLD pathogenesis. Nat Clin Pract Gastroenterol Hepatol. 2005;2(1):46-53.
  • Fabbrini E, et al. Obesity and liver disease. Gastroenterology. 2010;140(3):844-54.
  • Day CP, et al. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16(5):663-78.
  • Tilg H, et al. Cytokines and NAFLD. Gastroenterology. 2010;138(3):934-46.
  • Rinella ME. Nonalcoholic fatty liver disease. JAMA. 2015;313(22):2263-73.
  • Dulai PS, et al. Increased risk of mortality in NAFLD. Clin Gastroenterol Hepatol. 2018;16(4):602-12.
  • Takahashi Y, et al. Pathogenesis of NAFLD and NASH. J Clin Biochem Nutr. 2011;48(1):1-5.
  • Kleiner DE, et al. Histological scoring system for NAFLD. Hepatology. 2005;41(6):1313-21.
  • Clark JM, et al. The prevalence of NAFLD. J Gastroenterol Hepatol. 2003;18(3):280-88.
  • Sanyal AJ, et al. Pioglitazone for NAFLD. N Engl J Med. 2010;362(18):1675-85.
  • Vilar-Gomez E, et al. Weight loss and NAFLD. Gastroenterology. 2015;149(2):367-78.
  • Wong VW, et al. Non-invasive tests for NAFLD. J Hepatol. 2018;68(2):305-15.
  • Cusi K, et al. Treatment of NAFLD. Diabetes Care. 2016;39(8):1341-48.
  • Loomba R, et al. MRI-PDFF and NAFLD. Hepatology. 2015;61(4):1239-50.
  • Francque S, et al. Exercise and NAFLD. J Hepatol. 2019;70(4):728-30.
  • Sofi F, et al. Mediterranean diet and health. Am J Clin Nutr. 2010;92(5):1189-96.
  • Neuschwander-Tetri BA. Antioxidants for NAFLD. Hepatology. 2010;52(1):368-79.
  • Lefebvre P, et al. Role of FXR in NAFLD. Nat Rev Gastroenterol Hepatol. 2009;6(12):687-96.
  • Caldwell S, et al. Obeticholic acid in NAFLD. J Hepatol. 2017;67(3):541-49.
  • Adams LA, et al. Bariatric surgery for NAFLD. Hepatology. 2019;70(5):1215-25.
  • Kanwal F, et al. Risk of hepatocellular carcinoma in NAFLD. Hepatology. 2018;67(2):589-95.
  • Tsochatzis EA, et al. NAFLD fibrosis progression. J Hepatol. 2014;60(1):219-27.